Incannex submits ind application to the us fda for ihl-42x for obstructive sleep apnoea

Melbourne, australia, july 21, 2023 (globe newswire) -- incannex healthcare limited (nasdaq: ixhl) (asx: ihl), (‘incannex' or the ‘company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that it has successfully submitted an investigational new drug (‘ind') application to the us food and drug administration (‘fda') for ihl-42x for treatment of obstructive sleep apnoea.
IXHL Ratings Summary
IXHL Quant Ranking